These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29096839)

  • 1. Lipoprotein apheresis downregulates IL-1α, IL-6 and TNF-α mRNA expression in severe dyslipidaemia.
    Stefanutti C; Mazza F; Pasqualetti D; Di Giacomo S; Watts GF; Massari MS; de Neve J; Morozzi C; Fischer M
    Atheroscler Suppl; 2017 Nov; 30():200-208. PubMed ID: 29096839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipoprotein apheresis efficacy, challenges and outcomes: A descriptive analysis from the UK Lipoprotein Apheresis Registry, 1989-2017.
    Pottle A; Thompson G; Barbir M; Bayly G; Cegla J; Cramb R; Dawson T; Eatough R; Kale V; Neuwirth C; Nicholson K; Payne J; Scott J; Soran H; Walji S; Watkins S; Weedon H; Nath Datta DB
    Atherosclerosis; 2019 Nov; 290():44-51. PubMed ID: 31563836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Actual situation of lipoprotein apheresis in Saxony in 2013.
    Emmrich U; Hohenstein B; Julius U
    Atheroscler Suppl; 2015 May; 18():215-25. PubMed ID: 25936329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The incidence of cardiovascular events is largely reduced in patients with maximally tolerated drug therapy and lipoprotein apheresis. A single-center experience.
    Sampietro T; Sbrana F; Bigazzi F; Ripoli A; Dal Pino B; Pasanisi EM; Petersen C; Coceani M; Luciani R; Pianelli M
    Atheroscler Suppl; 2015 May; 18():268-72. PubMed ID: 25936336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein apheresis: state of the art and novelties.
    Stefanutti C; Julius U
    Atheroscler Suppl; 2013 Jan; 14(1):19-27. PubMed ID: 23357136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein apheresis in patients with peripheral artery disease and hyperlipoproteinemia(a).
    Poller WC; Dreger H; Morgera S; Berger A; Flessenkämper I; Enke-Melzer K
    Atheroscler Suppl; 2015 May; 18():187-93. PubMed ID: 25936325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany.
    Heigl F; Hettich R; Lotz N; Reeg H; Pflederer T; Osterkorn D; Osterkorn K; Klingel R
    Atheroscler Suppl; 2015 May; 18():154-62. PubMed ID: 25936320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between Sustained Reductions in Plasma Lipid and Lipoprotein Concentrations with Apheresis and Plasma Levels and mRNA Expression of PTX3 and Plasma Levels of hsCRP in Patients with HyperLp(a)lipoproteinemia.
    Stefanutti C; Mazza F; Steiner M; Watts GF; De Nève J; Pasqualetti D; Paal J
    Mediators Inflamm; 2016; 2016():4739512. PubMed ID: 26903710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apheresis to Mitigate Atherosclerotic Vascular Disease.
    Sachais BS; Shaz BH
    Am J Hypertens; 2018 Jul; 31(8):945-949. PubMed ID: 30016414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of lipoprotein apheresis on PCSK9 levels.
    Julius U; Milton M; Stoellner D; Rader D; Gordon B; Polk D; Waldmann E; Parhofer KG; Moriarty PM
    Atheroscler Suppl; 2015 May; 18():180-6. PubMed ID: 25936324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two low-density lipoprotein apheresis systems in patients with homozygous familial hypercholesterolemia.
    Drouin-Chartier JP; Tremblay AJ; Bergeron J; Pelletier M; Laflamme N; Lamarche B; Couture P
    J Clin Apher; 2016 Aug; 31(4):359-67. PubMed ID: 26011648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of lipoprotein apheresis with dextran-sulfate adsorption on the expression of genes involved in cardiovascular health in the blood of patients with homozygous familial hypercholesterolemia.
    Drouin-Chartier JP; Tremblay AJ; Bergeron J; Laflamme N; Lamarche B; Couture P
    J Clin Apher; 2018 Feb; 33(1):104-107. PubMed ID: 28712132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multicenter trial.
    Klingel R; Heibges A; Fassbender C
    Atheroscler Suppl; 2015 May; 18():35-40. PubMed ID: 25936302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run.
    Groß E; Hohenstein B; Julius U
    Atheroscler Suppl; 2015 May; 18():226-32. PubMed ID: 25936330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing plasma lysophosphatidylcholine levels in patients with regular dextran sulfate lipoprotein apheresis.
    Graessler J; Schuhmann K; Shevchenko A; Kopprasch S; Ban R; Bergmann S; Bornstein SR; Hohenstein B; Julius U
    Atheroscler Suppl; 2015 May; 18():170-5. PubMed ID: 25936322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoprotein apheresis in patients with peripheral artery disease and lipoprotein(a)-hyperlipoproteinemia: 2-year follow-up of a prospective single center study.
    Poller WC; Berger A; Dreger H; Morgera S; Enke-Melzer K
    Atheroscler Suppl; 2017 Nov; 30():174-179. PubMed ID: 29096834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein-apheresis in familial hypercholesterolemia: Long-term patient compliance in a French cohort.
    Beliard S; Gallo A; Duchêne E; Carrié A; Bittar R; Chapman MJ; Bruckert E; Saheb S
    Atherosclerosis; 2018 Oct; 277():66-71. PubMed ID: 30176566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: Seven case series and discussion.
    Ogura M; Makino H; Kamiya C; Yoshimatsu J; Soran H; Eatough R; Perrone G; Harada-Shiba M; Stefanutti C
    Atherosclerosis; 2016 Nov; 254():179-183. PubMed ID: 27755983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.
    Stefanutti C; Blom DJ; Averna MR; Meagher EA; Theron Hd; Marais AD; Hegele RA; Sirtori CR; Shah PK; Gaudet D; Vigna GB; Sachais BS; Di Giacomo S; du Plessis AM; Bloedon LT; Balser J; Rader DJ; Cuchel M;
    Atherosclerosis; 2015 Jun; 240(2):408-14. PubMed ID: 25897792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein apheresis--more than just cholesterol reduction?
    Neumann CL; Schulz EG; Hagenah GC; Platzer U; Wieland E; Schettler V
    Atheroscler Suppl; 2013 Jan; 14(1):29-32. PubMed ID: 23357137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.